Gland Pharma Limited – Q4 FY26 Results

key financial highlights

• Revenue from Operations:
  • Revenue (Q4 FY26): ₹17,427.90 Million
    • QoQ Change: +2.80%
    • YoY Change: +22.31%
  • Previous Quarter (Q3 FY26): ₹16,953.63 Million
  • Previous Year (Q4 FY25): ₹14,249.09 Million
• Profit After Tax (PAT):
  • PAT (Q4 FY26): ₹3,666.75 Million
    • QoQ Change: +40.24%
    • YoY Change:+96.57%
  • Previous Quarter (Q3 FY26): ₹2,614.75 Million
  • Previous Year (Q4 FY25): ₹1,865.41 Million
• QoQ Performance:
  • Revenue Trend: Sequential revenue growth remained healthy despite a high operational base in previous quarters.
    
  • Profit Trend: Profitability improved sharply QoQ supported by stable expenses and stronger operational margins.

Margin Analysis

Drivers:

• Better operational efficiency improved earnings conversion.
• Employee cost growth remained controlled relative to revenue expansion.
• Inventory adjustments supported margin improvement.
• Finance costs remained manageable.
• Higher scale supported operating leverage.

Insight:

• The company demonstrated meaningful improvement in profitability metrics, reflecting stronger business execution and margin stability.

Earning quality check

Key Drivers:

• Strong operating cash flow generation.
• Net cash generated from operations increased YoY.
• Healthy cash reserves on balance sheet.
• Strong profitability conversion into free cash flow.
• Low leverage profile maintained.

Interpretations:

• Earnings quality remained strong with substantial operational cash generation and improving profitability supported by core business performance.

balance sheet Analysis

• Total Assets: ₹125,108.48 Million
• Total Liabilities: ₹16,084.03 Million

Insight:

• The company maintained a very strong balance sheet with substantial cash reserves, high equity base, and low financial leverage, supporting future expansion and stability.

key risks

• Regulatory risks in international pharmaceutical markets.
• Pricing pressure in generic drug segments.
• Currency fluctuation risks due to export exposure.
• Compliance and manufacturing audit risks.
• Competitive pressure in injectable products.
• Dependence on regulated market approvals.

management strategy signals

Focus Area:

• Expanding global pharmaceutical presence.
• Improving manufacturing scale and efficiencies.
• Strengthening injectable product portfolio.
• Enhancing regulated market penetration.
• Maintaining compliance and quality standards.
• Driving operational excellence and margin expansion.

Financial metrics table

Quarterly Performance Context